Remember Me     Forgot Login?   Sign up   •  Web site Help & Info

!!! DISCUSSION GROUP RULES !!!

1. You must be a registered website user in order to post and comment. Guests may read only.
2. Be kind and helpful, not rude and cynical.
3. Don't advertise or promote anything. You will be banned from the group.
4. Report problems to the moderators. THANK YOU!

PDSA Announcements

Rigel's bleeding disorder drug clears first of two

  • Jeff
  • Topic Author
  • Offline
  • I am the PDSA web guy, and also help with PDSA's social media accounts, like Facebook, Twitter, Instagram, etc.
More
7 years 10 months ago #55474 by Jeff
"The drug, fostamatinib, is being studied to treat chronic immune thrombocytopenia (ITP) in which the immune system attacks and destroys the body's own blood platelets.

About 18 percent of the 76 adult patients who were treated with fostamatinib achieved a stable platelet response in the study, compared with none on placebo.

Patients typically had an increase in platelet counts to a level above 50,000/uL within the initial weeks of treatment."

- From Reuters Health News

READ MORE

Jeff Cooper, PDSA website guy
The following user(s) said Thank You: Channer

Please Log in or Create an account to join the conversation.